{
  "version": 3,
  "created_at": "2026-07-12T15:37:33.945Z",
  "task_summary": "Generate integrated business plan and scientific report with dual-program strategy (pMHC + Program B STK11/SIK3 adjunct)",
  "agents": [],
  "phases": [
    {
      "name": "Plan",
      "delegations": [
        {
          "steps": [
            {
              "title": "Integrated program architecture & positioning",
              "description": "Synthesize Program A/B findings with the core pMHC-II therapeutic platform: (1) recap pMHC-II monotherapy validation (dairy epitope, Phase 1-5 roadmap, manufacturing specs); (2) articulate Program B rationale as a mechanistically coherent *optional* adjunct using STK11/SIK3 inhibition to de-lock committed Th2 effectors and enhance pMHC-induced tolerance conversion; (3) positioning as 'pMHC alone' vs 'pMHC + SIK3i' dual-path strategy; (4) IP/landscape considerations. Produce: integrated architecture diagram, decision-tree showing go/no-go gates, market positioning brief."
            },
            {
              "title": "Updated preclinical roadmap (5-phase) with two tracks",
              "description": "Expand Phase 1-5 roadmap from existing manuscript to include optional Program B workstream: Phase 1 adds ex vivo combination experiment (STK11/SIK3 knockdown + pMHC-II construct co-culture, TR1/iTreg/suppression readouts, antigen rechallenge); Phase 2 adds mouse tolerization model with optional co-dosing (pMHC NP alone vs. pMHC + SIK3i, eosinophil readout); Phase 3 GLP extends to combination safety package. Maintain gate criteria for each program's go/no-go. Produce: detailed 18-24 month dual-track roadmap, updated budget ($275-457k pMHC → $310-520k with Program B), risk matrix with dual-program branches."
            },
            {
              "title": "Scientific validation strategy & killer experiments",
              "description": "Design the three de-risking experiments from the program assessment: (1) cross-validation in EoE patient PBMC/esophageal biopsies (STK11/SIK3 effect in disease tissue); (2) combinatorial conversion assay (CD4 + STK11/SIK3 perturbation + tolerogenic pMHC construct, with rechallenge); (3) selectivity counter-screen (Th1/Th17/Treg cross-reactivity). Lay out technical specs, readouts, sample sizes, timelines. Produce: validation brief with 3-step de-risking plan, success criteria, failure modes."
            },
            {
              "title": "Commercial & licensing strategy",
              "description": "Two-scenario market analysis: (1) pMHC-II monotherapy pathway (simpler, comparable to Navacim/existing tolerogenic immunotherapies); (2) pMHC + SIK3i combination pathway (differentiated, higher complexity, orphan advantage). IP strategy for both (composition-of-matter, co-targeting, methods-of-use). Biotech partnering angles (which partner profile best-suited for monotherapy vs. combo). Addressable market sizing. Produce: commercial brief with 'monotherapy' vs 'combination' go-paths, partner profile matrix, licensing strategy."
            },
            {
              "title": "Final integrated business & scientific report (PDF + markdown)",
              "description": "Comprehensive 25-35 page report synthesizing: executive summary (dual-program strategy, validation status, timeline, budget), background (EoE unmet need, pMHC rationale, perturbseq findings), scientific strategy (pMHC design, Program B mechanism, combination hypothesis, de-risking experiments), preclinical roadmap (5-phase dual-track), financial plan ($310-520k, phase breakdown), regulatory path (IND readiness, multi-HLA roadmap, combination CMC), commercialization (market sizing, IP, partnering), and risk/mitigation matrix. Cite all prior artifacts. Produce: integrated_eoe_business_scientific_report.pdf + markdown source, ready for biotech pitch/regulatory/partner review."
            }
          ]
        }
      ],
      "id": "phase-0"
    }
  ],
  "desired_outputs": [
    "Integrated business & scientific report (PDF + markdown)",
    "Updated 5-phase dual-track roadmap with budget & timelines",
    "Program architecture & positioning brief",
    "Validation strategy & de-risking experiment specs",
    "Commercial strategy brief (monotherapy vs. combination paths)"
  ],
  "feasibility": {
    "confidence": "high",
    "rationale": "All foundational work (pMHC design, peer review, perturbseq analysis, program assessment) is complete and documented. Deliverables require synthesis and integration of existing artifacts, not new analysis or computation. Two clear go-paths (monotherapy vs. combination) are well-defined with vetted de-risking experiments."
  }
}